Sugi Predict

Sugi Predict / Compounds / SCHEMBL7712243

SCHEMBL7712243

SCHEMBL7712243

CN(C)CCN1C(=O)c2cc([N+](=O)[O-])cc3cc([N+](=O)[O-])cc(c23)C1=O

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FTO Q9C0B1 3/20 0.81
▸ PABPC1 P11940 3/20 0.81
▸ HEXA P06865 1/20 0.54
▸ HEXB P07686 1/20 0.54
▸ LCK P06239 1/20 0.53
▸ POLB P06746 4/20 0.52
▸ MEN1 O00255 3/20 0.52
▸ KMT2A Q03164 3/20 0.52
▸ KDM4E B2RXH2 3/20 0.52
▸ MAPT P10636 2/20 0.52
▸ RAD52 P43351 2/20 0.52
▸ S1PR1 P21453 1/20 0.52
▸ HTT P42858 1/20 0.52
▸ RECQL P46063 1/20 0.52
▸ RAB9A P51151 1/20 0.52
▸ PAX8 Q06710 1/20 0.52
▸ CYP2D6 P10635 1/20 0.51
▸ TERT O14746 2/20 0.48
▸ CA12 O43570 2/20 0.47
▸ CA1 P00915 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9017071 0.93 FTO (0.71) FTOPABPC1HEXAHEXBLCK
Mitonafide SCHEMBL62046 0.90 FTO (1.00) FTOPABPC1HEXAHEXBLCK
Mitonafide SCHEMBL29352711 0.90 FTO (1.00) FTOPABPC1HEXAHEXBLCK
Mitonafide SCHEMBL29499462 0.90 FTO (1.00) FTOPABPC1HEXAHEXBLCK
Mitonafide SCHEMBL5166813 0.89 FTO (0.98) FTOPABPC1HEXAHEXBLCK
SCHEMBL9017061 0.87 FTO (0.64) FTOPABPC1HEXAHEXBLCK
SCHEMBL10340122 0.86 FTO (0.63) FTOPABPC1LCKPOLBMEN1
Hydrochloric Acid SCHEMBL10340360 0.85 FTO (0.62) FTOPABPC1LCKPOLBMEN1
Mitonafide SCHEMBL5781995 0.84 FTO (0.88) FTOPABPC1HEXAHEXBLCK
SCHEMBL9017091 0.83 FTO (0.59) FTOPABPC1HEXAHEXBLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130005759-A1 SMALL MOLECULE MODIFIERS OF MICRORNA MIR-122 NORTH CAROLINA STATE UNIVERSITY 2013-01-03 — — US claimed
EP-0125439-B1 3,6-DISUBSTITUTED-1,8-NAPHTHALIMIDES AND METHODS FOR THEIR PRODUCTION AND USE WARNER-LAMBERT COMPANY (US) 1990-01-24 — — EP claimed
US-4499266-A MICROBIOCIDES AND ANTICARCINOGENIC WARNER-LAMBERT COMPANY (US) 1985-02-12 — — US claimed
EP-0125439-A2 3,6-Disubstituted-1,8-naphthalimides and methods for their production and use WARNER-LAMBERT COMPANY (US) 1984-11-21 — — EP claimed
US-20130005759-A1 SMALL MOLECULE MODIFIERS OF MICRORNA MIR-122 NORTH CAROLINA STATE UNIVERSITY 2013-01-03 — — US disclosed
US-20130005759-A1 SMALL MOLECULE MODIFIERS OF MICRORNA MIR-122 NORTH CAROLINA STATE UNIVERSITY 2013-01-03 — — US disclosed
US-20130005759-A1 SMALL MOLECULE MODIFIERS OF MICRORNA MIR-122 NORTH CAROLINA STATE UNIVERSITY 2013-01-03 — — US disclosed
WO-2011091209-A1 SMALL MOLECULE MODIFIERS OF MICRORNA MIR-122 NORTH CAROLINA STATE UNIVERSITY (US) 2011-07-28 — — WO disclosed
US-6362181-B1 BACTERICIDES; ENZYME INHIBITORS; ANTITUMOR AGENTS WARNER-LAMBERT COMPANY 2002-03-26 — — US disclosed
US-6177423-B1 N-(HYDROXY OR PROTECTED HYDROXY)-BENZO(DE)ISOQUINOLINE-1,3-DIONE DERIVATIVES; BACTERIAL DNA GYRASE AND DNA TOPOISOMERASE INHIBITORS USEFUL FOR ANTIBACTERIAL AGENTS HAVING REDUCED DRUG RESISTANCE AND REDUCED SIDE EFFECTS WARNER-LAMBERT COMPANY 2001-01-23 — — US disclosed
EP-0939754-A2 N-OXY-NAPHTHALIMIDES AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 1999-09-08 — — EP disclosed
WO-1998019648-A2 N-OXY-NAPHTHALIMIDES AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 1998-05-14 — — WO disclosed
EP-0268093-B1 5-Nitrobenzo[de]isoquinoline-1,3 diones, their preparation and use KNOLL AG (DE) 1992-05-13 — — EP disclosed
EP-0125439-B1 3,6-DISUBSTITUTED-1,8-NAPHTHALIMIDES AND METHODS FOR THEIR PRODUCTION AND USE WARNER-LAMBERT COMPANY (US) 1990-01-24 — — EP disclosed
EP-0268093-A1 5-Nitrobenzo[de]isoquinoline-1,3 diones, their preparation and use KNOLL AG (DE) 1988-05-25 — — EP disclosed
US-4665071-A ANTITUMOR AGENTS WARNER-LAMBERT COMPANY (US) 1987-05-12 — — US disclosed
US-4614820-A ANTIMICROBIAL AND ANTITUMOR AGENTS WARNER-LAMBERT CO. (US) 1986-09-30 — — US disclosed
US-4594346-A Antileukemia agent WARNER-LAMBERT COMPANY (US) 1986-06-10 — — US disclosed
US-4499266-A MICROBIOCIDES AND ANTICARCINOGENIC WARNER-LAMBERT COMPANY (US) 1985-02-12 — — US disclosed
EP-0125439-A2 3,6-Disubstituted-1,8-naphthalimides and methods for their production and use WARNER-LAMBERT COMPANY (US) 1984-11-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005759-A1 SMALL MOLECULE MODIFIERS OF MICRORNA MIR-122 HAVCR2, CCAR2, EIF2AK2 FTO 4828/4885PABPC1 1548/4885HEXA 3252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.